Just finished recording the next IDSA podcast with the remarkable Courtney Harris, MD, FACP, who shared her top tips on the job search process for ID fellows. She's thought a lot about this topic -- check out her paper!
Full recording coming soon.
doi.org/10.1111/tid.14…

Excellent summary of a clinical trial likely to change clinical practice.

Can't wait to see the full study.

Each year, during ECCMID in Europe -- now called #ESCMIDGlobal -- I'm reminded of the first time I saw the power of this platform for education, as I didn't attend but learned SO MUCH from colleagues.

Hope we can keep it that way! x.com/PaulSaxMD/stat…

The guest on this latest #LetsTalkID podcast is none other than the wonderful Darcy Wooten she/her. The first time someone emailed me about her they wrote, “She is the kind of individual who brightens the life of everyone she works with and teaches.” So true! podcasts.apple.com/us/podcast/let…

Hey insurance companies and pharmacy benefit managers and pharmacies -- requiring a prior approval and inflating the charge for a cheap generic drug makes zero sense!

It's bad for patients and is unethical.

Stop it already!

Exhibit #1: Linezolid. blogs.jwatch.org/hiv-id-observa…

Hey #IDTwitter -- do you think the data support these recommendations? Why or why not?

(h/t a great talk by one of our senior fellows, Dr. Hayden Andrews)

Consensus Guidelines for Anal Cancer Screening doi.org/10.1002/ijc.34…

Time to re-post this one blogs.jwatch.org/hiv-id-observa…

A common theory behind increased RSV cases numbers among children after the end of Covid lockdowns was “immunity debt”. In this fascinating analysis now in Clinical Infectious Diseases, another explanation emerges--vastly increased testing, esp of older kids. sabeti_lab doi.org/10.1093/cid/ci…

It's been a while since I've written something about Paxlovid ... which probably is telling us something. 🤷‍♂️Here's the latest on our 'preferred' outpatient treatment for Covid. blogs.jwatch.org/hiv-id-observa…

Since this is an HIV treatment issue, and none of my peers in HIV/ID work for this insurance company, I find this description of the person I'll be speaking with exceedingly unlikely

Not only is my ID colleague Brian Chan very funny, but he can spin an April 1st post better than anyone

These reports of ceftriaxone-resistant gonorrhea are appropriately receiving much attention.

Can anyone with experience with such cases comment on the clinical manifestations? Difficult to find this information. cdc.gov/mmwr/volumes/7…

Delighted to share this #croi2024 highlights review with Eileen Scully, who covers translational science better than anyone!

(I do the easy part -- the clinical research.)

It was an exciting conference this year -- hope you enjoy this summary! hivvirology.com/croi-highlight…

Inspired by a trio of outstanding MGH/BWH Infectious Diseases Fellowship, I'm writing about the antibiotic we love to hate, and hate to love -- vancomycin.

Very hard to justify it in the outpatient setting, where there are almost always safer and more convenient alternatives. blogs.jwatch.org/hiv-id-observa…